Mobility paves Samsung’s silver path
The Korean giant’s early bet on mobile phones helped it hit the $10-bn mark in India, but in its 25th year it ...
Strides Pharma Science expects to disrupt the high-volume insulin and analogues space with high-speed filling technology developed in-house to deliver insulin.
“The high-speed filling technology is our in-house development and this is expected to disrupt the high-volume insulin and analogue space, especially in glargine, lispro and rh-Insulin,”R Ananthanarayanan, Managing Director and CEO, Strides Pharma Sciences, told BusinessLine.
“Our vaccine lines equipment installation is to start in December 2020 and a vaccine suite for multiple vaccine types will go on-stream from January 2021. This will give us high-speed filling lines with a yearly capacity of 500 million doses of liquid vaccines and 300 million doses of lyophilised vaccines,” he added.
The company’s production lines cater to vaccine types including viral vector, protein sub-unit, RNA and DNA. Currently, it is in the middle of discussions with global companies developing vaccines for Covid-19.
“Strides’ commitment to invest additional $40m in Stelis Biopharma for a majority stake in the biotech business is ongoing in accordance with our commitment. We have already invested around $31million in it. Operationally, Stelis Biopharma is expected to break even in FY’22.
“Within Stelis, from the manufacturing capacity standpoint, out of our five manufacturing suites, four are now fully commercial, validated and available for business. From the IP (intellectual property) standpoint, we completed the EU filing for our first biosimilar PTH (Teriparatide) in Q2FY21. The product is currently under review. The US development for the product is on track. The US front-end for the product will be managed by Strides,” he said.
Talking about the Covid-19 impact on the company, Ananthanarayanan said: “It impacted inventory depletion on a few stock-keeping units at our front-ends and stock-outs for certain products, mainly in the US. It also resulted in lower order fulfilment, predominantly in other regulated markets including supplies to Australia.”
In the US, the company faced pricing pressure in select products and stock-outs for a few products posed certain challenges. “But overall, we are happy with the outcome in spite of the challenges we faced in the region this quarter. We had an 8 per cent q-o-q growth. Our outlook for the US market remains positive and we are confident of our growth trajectory. We see a great opportunity for us to continue building on our existing customer advocacy.
“The UK and some parts of Europe were impacted by lower pharmacy footfall, lower surgeries in hospitals, leading to lower prescription generations. But moving forward, the order book in these areas looks healthy and we are expecting a rebound in H2FY21.”
The Korean giant’s early bet on mobile phones helped it hit the $10-bn mark in India, but in its 25th year it ...
Antrix should adopt a different tactic than merely fighting over jurisdiction: Experts
Invest in relationships, enterprise, behaviour, effort and learning
From different types of osmoses to new membranes, researchers have come up with ways of drawing water
Only half the Sensex stocks have bettered the index’s return in the last 10,000-point journey
High valuation and stiff competition from larger players are a dampener
Investors with a short-term perspective can buy The New India Assurance Company (NIACL) stock at current ...
₹1490 • HDFC Bank S1S2R1R2COMMENT 1475146015051520 Fresh short positions are recommended with a stiff ...
What makes the new crop of young Indian cricketers such game-changing winners? Over and above their talent, ...
In these isolated times when people yearn for a slice of the familiar, amateur and professional chefs are ...
‘You ready to go to work?’ Joe Biden had asked Kamala Harris before naming her as his running mate. ‘Oh my ...
Writer Narendra’s latest book, rich with vignettes from Bastar and his native village in Uttar Pradesh, ...
Digital is becoming dominant media, but are companies and their ad agencies transforming fast enough to make a ...
Slow Network, promoted by journalist-lyricist Neelesh Misra, pushes rural products and experiences
How marketers can use the traditional exchange of festive wishes meaningfully
For Fortune, a brand celebrating its 20th anniversary, it was a rude shock to become the butt of social media ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor